CA2491002A1 - Nouvelle combinaison - Google Patents

Nouvelle combinaison Download PDF

Info

Publication number
CA2491002A1
CA2491002A1 CA002491002A CA2491002A CA2491002A1 CA 2491002 A1 CA2491002 A1 CA 2491002A1 CA 002491002 A CA002491002 A CA 002491002A CA 2491002 A CA2491002 A CA 2491002A CA 2491002 A1 CA2491002 A1 CA 2491002A1
Authority
CA
Canada
Prior art keywords
hypertension
inhibitor
pde5
angiotensin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491002A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
David Nathan Abraham Fox
Bernadette Hughes
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., David Nathan Abraham Fox, Bernadette Hughes, Pfizer Limited filed Critical Pfizer Inc.
Publication of CA2491002A1 publication Critical patent/CA2491002A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002491002A 2002-06-26 2003-06-16 Nouvelle combinaison Abandoned CA2491002A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0214784.1 2002-06-26
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (fr) 2002-06-26 2003-06-16 Nouvelle combinaison

Publications (1)

Publication Number Publication Date
CA2491002A1 true CA2491002A1 (fr) 2004-01-08

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491002A Abandoned CA2491002A1 (fr) 2002-06-26 2003-06-16 Nouvelle combinaison

Country Status (20)

Country Link
EP (1) EP1524996A2 (fr)
JP (1) JP2005531627A (fr)
KR (1) KR20050013156A (fr)
CN (1) CN1662257A (fr)
AR (1) AR040337A1 (fr)
AU (1) AU2003242895A1 (fr)
BR (1) BR0312030A (fr)
CA (1) CA2491002A1 (fr)
GB (1) GB0214784D0 (fr)
GT (1) GT200300124A (fr)
MX (1) MXPA04012569A (fr)
NO (1) NO20050400L (fr)
PA (1) PA8575501A1 (fr)
PE (1) PE20040868A1 (fr)
PL (1) PL375079A1 (fr)
RU (1) RU2004136276A (fr)
TW (1) TW200404546A (fr)
UY (1) UY27863A1 (fr)
WO (1) WO2004002461A2 (fr)
ZA (1) ZA200409532B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
CN101332080A (zh) * 2002-07-26 2008-12-31 奥林巴斯株式会社 图像处理系统
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
NZ564369A (en) * 2005-06-10 2010-03-26 Dong A Pharm Co Ltd 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases
EP1909793A2 (fr) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
JP2009512711A (ja) * 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007134136A2 (fr) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19881732D2 (de) * 1997-11-12 2000-08-24 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
SK4562002A3 (en) * 1999-10-11 2003-04-01 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CN1446084A (zh) * 2000-08-11 2003-10-01 辉瑞大药厂 胰岛素抗性综合症的治疗

Also Published As

Publication number Publication date
PA8575501A1 (es) 2003-12-30
WO2004002461A3 (fr) 2004-05-13
GT200300124A (es) 2004-03-17
KR20050013156A (ko) 2005-02-02
BR0312030A (pt) 2005-03-22
JP2005531627A (ja) 2005-10-20
TW200404546A (en) 2004-04-01
WO2004002461A2 (fr) 2004-01-08
MXPA04012569A (es) 2005-04-19
PL375079A1 (en) 2005-11-14
RU2004136276A (ru) 2005-09-10
GB0214784D0 (en) 2002-08-07
UY27863A1 (es) 2003-12-31
CN1662257A (zh) 2005-08-31
EP1524996A2 (fr) 2005-04-27
AU2003242895A1 (en) 2004-01-19
NO20050400L (no) 2005-03-29
PE20040868A1 (es) 2004-11-25
ZA200409532B (en) 2006-06-28
AR040337A1 (es) 2005-03-30

Similar Documents

Publication Publication Date Title
US20080318982A1 (en) Pharmaceutical Combination for the Treatment of Luts
US20040186046A1 (en) Treatment of type 1 diabetes with PDE5 inhibitors
US8329656B2 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
JP2004506009A (ja) インスリン抵抗性症候群の治療
MXPA04007430A (es) Uso de inhibidores de pde5 en el tratamiento de cicatrices y fibrosis.
EP1313478A2 (fr) Traitement de la migraine par des inhibiteurs de pde5
CA2485984A1 (fr) Nouvelle combinaison
CA2491002A1 (fr) Nouvelle combinaison
US20040132731A1 (en) Novel combination
US20040077624A1 (en) Novel combination
JP2006520777A (ja) Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
US20030216407A1 (en) Use of PDE5 inhibitors in the treatment of scarring
EP1157705A2 (fr) Utilisation d'un inhibiteur de la phosphodiestérase dans la fabrication d'un médicament destiné à la stabilisation de la pression sanguine lors de l'hémodialyse
US20050148585A1 (en) Treatment of wounds
WO2003047588A1 (fr) Necessaire pour reduire la douleur provoquee par les inhibiteurs des pde-v
KR100595807B1 (ko) 조루 치료법
AU2001276636A1 (en) Treatment of wounds
JP4533590B2 (ja) 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
EP1759700A1 (fr) Utilisation d'inhibiteurs de PDE5 pour traiter et prévenir les maladies liées à la hypopigmentation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued